Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes
Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2012
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22849
- Acceso en línea:
- https://doi.org/10.3810/pgm.2012.07.2560
https://repository.urosario.edu.co/handle/10336/22849
- Palabra clave:
- Apolipoprotein A1
Apolipoprotein B
Colesevelam
Hemoglobin a1c
Low density lipoprotein cholesterol
Metformin
Placebo
Triacylglycerol
Allylamine
Antidiabetic agent
Cholesterol
Colesevelam
Drug derivative
Glycosylated hemoglobin
Hypocholesterolemic agent
Lipoprotein
Metformin
Abdominal distension
Abdominal pain
Adult
Article
Cholesterol blood level
Cohort analysis
Constipation
Controlled study
Diarrhea
Drug dose titration
Drug efficacy
Drug response
Drug safety
Drug withdrawal
Dyspepsia
Female
Flatulence
Gastritis
Hispanic
Human
Major clinical study
Male
Multicenter study (topic)
Nausea
Non insulin dependent diabetes mellitus
Post hoc analysis
Randomized controlled trial (topic)
Triacylglycerol blood level
Vomiting
Blood
Clinical trial
Controlled clinical trial
Double blind procedure
Drug combination
Ethnology
Hispanic
Randomized controlled trial
Treatment outcome
Allylamine
Anticholesteremic Agents
Cholesterol
Double-Blind Method
Female
Hispanic Americans
Humans
Hypoglycemic Agents
Lipoproteins
Male
Metformin
Treatment Outcome
Bile acid sequestrant
Colesevelam
Hispanic
Metformin
Type 2 diabetes mellitus
Type 2
Combination
Glycosylated
Diabetes Mellitus
Drug Therapy
Hemoglobin A
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_7f3541e1ab7a03c74a3de45f97ef42b5 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/22849 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
4403950a-3485-404c-9480-053c8a4ed106-1e6f89c9d-8da5-4308-9b33-020e62b46fd6-1ec7eed0b-539a-4ea6-9a42-5a4b3a96c349-146274e04-8cc9-4c10-b28a-f9268538f022-193c4ebbf-6ea9-40c8-81e9-efdd8c81f4a3-1882c9aa6-f061-4398-9c78-3547a5c1d848-12020-05-25T23:58:22Z2020-05-25T23:58:22Z2012Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were randomized to metformin plus colesevelam or metformin plus placebo. The primary effcacy parameter was the mean change in glycated hemoglobin (HbA1c) levels from baseline. Results: Metformin plus colesevelam had a greater mean HbA1c reduction (-1.2 ± 0.1%) than metformin plus placebo (-0.8 ± 0.1%; P = 0.001) from mean baselines of 7.7% and 7.6%, respectively. Low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein (apo) B levels were also reduced (P and lt; 0.0001 for all), while triglyceride (P and lt; 0.0001) and apoA-I (P and lt; 0.05) levels were increased with metformin plus colesevelam treatment compared with metformin plus placebo. With metformin plus colesevelam versus metformin plus placebo, more patients achieved an HbA1c of, 7.0% (75% vs 56%) and LDL-C of, 100 mg/dL (49% vs 14%; both P, 0.05). Conclusion: Metformin plus colesevelam may be an effective initial treatment option for Hispanic patients with early type 2 diabetes mellitus. © Postgraduate Medicine.application/pdfhttps://doi.org/10.3810/pgm.2012.07.2560325481https://repository.urosario.edu.co/handle/10336/22849engMedquest Communications LLC13No. 47Postgraduate MedicineVol. 124Postgraduate Medicine, ISSN:325481, Vol.124, No.4 (2012); pp. 7-13https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871672045&doi=10.3810%2fpgm.2012.07.2560&partnerID=40&md5=21be1c7dca5cef8c3cdceae6cbfe21b5Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURApolipoprotein A1Apolipoprotein BColesevelamHemoglobin a1cLow density lipoprotein cholesterolMetforminPlaceboTriacylglycerolAllylamineAntidiabetic agentCholesterolColesevelamDrug derivativeGlycosylated hemoglobinHypocholesterolemic agentLipoproteinMetforminAbdominal distensionAbdominal painAdultArticleCholesterol blood levelCohort analysisConstipationControlled studyDiarrheaDrug dose titrationDrug efficacyDrug responseDrug safetyDrug withdrawalDyspepsiaFemaleFlatulenceGastritisHispanicHumanMajor clinical studyMaleMulticenter study (topic)NauseaNon insulin dependent diabetes mellitusPost hoc analysisRandomized controlled trial (topic)Triacylglycerol blood levelVomitingBloodClinical trialControlled clinical trialDouble blind procedureDrug combinationEthnologyHispanicRandomized controlled trialTreatment outcomeAllylamineAnticholesteremic AgentsCholesterolDouble-Blind MethodFemaleHispanic AmericansHumansHypoglycemic AgentsLipoproteinsMaleMetforminTreatment OutcomeBile acid sequestrantColesevelamHispanicMetforminType 2 diabetes mellitusType 2CombinationGlycosylatedDiabetes MellitusDrug TherapyHemoglobin AInitial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetesarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Rosenstock, JulioHernandez-Triana, EricHandelsman, YehudaMisir, SoamnauthJones, Michael R.Nagendran, Sukumar10336/22849oai:repository.urosario.edu.co:10336/228492022-05-02 07:37:14.398152https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
title |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
spellingShingle |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes Apolipoprotein A1 Apolipoprotein B Colesevelam Hemoglobin a1c Low density lipoprotein cholesterol Metformin Placebo Triacylglycerol Allylamine Antidiabetic agent Cholesterol Colesevelam Drug derivative Glycosylated hemoglobin Hypocholesterolemic agent Lipoprotein Metformin Abdominal distension Abdominal pain Adult Article Cholesterol blood level Cohort analysis Constipation Controlled study Diarrhea Drug dose titration Drug efficacy Drug response Drug safety Drug withdrawal Dyspepsia Female Flatulence Gastritis Hispanic Human Major clinical study Male Multicenter study (topic) Nausea Non insulin dependent diabetes mellitus Post hoc analysis Randomized controlled trial (topic) Triacylglycerol blood level Vomiting Blood Clinical trial Controlled clinical trial Double blind procedure Drug combination Ethnology Hispanic Randomized controlled trial Treatment outcome Allylamine Anticholesteremic Agents Cholesterol Double-Blind Method Female Hispanic Americans Humans Hypoglycemic Agents Lipoproteins Male Metformin Treatment Outcome Bile acid sequestrant Colesevelam Hispanic Metformin Type 2 diabetes mellitus Type 2 Combination Glycosylated Diabetes Mellitus Drug Therapy Hemoglobin A |
title_short |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
title_full |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
title_fullStr |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
title_full_unstemmed |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
title_sort |
Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes |
dc.subject.keyword.spa.fl_str_mv |
Apolipoprotein A1 Apolipoprotein B Colesevelam Hemoglobin a1c Low density lipoprotein cholesterol Metformin Placebo Triacylglycerol Allylamine Antidiabetic agent Cholesterol Colesevelam Drug derivative Glycosylated hemoglobin Hypocholesterolemic agent Lipoprotein Metformin Abdominal distension Abdominal pain Adult Article Cholesterol blood level Cohort analysis Constipation Controlled study Diarrhea Drug dose titration Drug efficacy Drug response Drug safety Drug withdrawal Dyspepsia Female Flatulence Gastritis Hispanic Human Major clinical study Male Multicenter study (topic) Nausea Non insulin dependent diabetes mellitus Post hoc analysis Randomized controlled trial (topic) Triacylglycerol blood level Vomiting Blood Clinical trial Controlled clinical trial Double blind procedure Drug combination Ethnology Hispanic Randomized controlled trial Treatment outcome Allylamine Anticholesteremic Agents Cholesterol Double-Blind Method Female Hispanic Americans Humans Hypoglycemic Agents Lipoproteins Male Metformin Treatment Outcome Bile acid sequestrant Colesevelam Hispanic Metformin Type 2 diabetes mellitus |
topic |
Apolipoprotein A1 Apolipoprotein B Colesevelam Hemoglobin a1c Low density lipoprotein cholesterol Metformin Placebo Triacylglycerol Allylamine Antidiabetic agent Cholesterol Colesevelam Drug derivative Glycosylated hemoglobin Hypocholesterolemic agent Lipoprotein Metformin Abdominal distension Abdominal pain Adult Article Cholesterol blood level Cohort analysis Constipation Controlled study Diarrhea Drug dose titration Drug efficacy Drug response Drug safety Drug withdrawal Dyspepsia Female Flatulence Gastritis Hispanic Human Major clinical study Male Multicenter study (topic) Nausea Non insulin dependent diabetes mellitus Post hoc analysis Randomized controlled trial (topic) Triacylglycerol blood level Vomiting Blood Clinical trial Controlled clinical trial Double blind procedure Drug combination Ethnology Hispanic Randomized controlled trial Treatment outcome Allylamine Anticholesteremic Agents Cholesterol Double-Blind Method Female Hispanic Americans Humans Hypoglycemic Agents Lipoproteins Male Metformin Treatment Outcome Bile acid sequestrant Colesevelam Hispanic Metformin Type 2 diabetes mellitus Type 2 Combination Glycosylated Diabetes Mellitus Drug Therapy Hemoglobin A |
dc.subject.keyword.eng.fl_str_mv |
Type 2 Combination Glycosylated Diabetes Mellitus Drug Therapy Hemoglobin A |
description |
Objective: To evaluate initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with type 2 diabetes mellitus. Research Design and Methods: Patients self-identifed as Hispanic from a previous study were included in this exploratory post hoc analysis. Patients were randomized to metformin plus colesevelam or metformin plus placebo. The primary effcacy parameter was the mean change in glycated hemoglobin (HbA1c) levels from baseline. Results: Metformin plus colesevelam had a greater mean HbA1c reduction (-1.2 ± 0.1%) than metformin plus placebo (-0.8 ± 0.1%; P = 0.001) from mean baselines of 7.7% and 7.6%, respectively. Low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein (apo) B levels were also reduced (P and lt; 0.0001 for all), while triglyceride (P and lt; 0.0001) and apoA-I (P and lt; 0.05) levels were increased with metformin plus colesevelam treatment compared with metformin plus placebo. With metformin plus colesevelam versus metformin plus placebo, more patients achieved an HbA1c of, 7.0% (75% vs 56%) and LDL-C of, 100 mg/dL (49% vs 14%; both P, 0.05). Conclusion: Metformin plus colesevelam may be an effective initial treatment option for Hispanic patients with early type 2 diabetes mellitus. © Postgraduate Medicine. |
publishDate |
2012 |
dc.date.created.spa.fl_str_mv |
2012 |
dc.date.accessioned.none.fl_str_mv |
2020-05-25T23:58:22Z |
dc.date.available.none.fl_str_mv |
2020-05-25T23:58:22Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3810/pgm.2012.07.2560 |
dc.identifier.issn.none.fl_str_mv |
325481 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/22849 |
url |
https://doi.org/10.3810/pgm.2012.07.2560 https://repository.urosario.edu.co/handle/10336/22849 |
identifier_str_mv |
325481 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
13 |
dc.relation.citationIssue.none.fl_str_mv |
No. 4 |
dc.relation.citationStartPage.none.fl_str_mv |
7 |
dc.relation.citationTitle.none.fl_str_mv |
Postgraduate Medicine |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 124 |
dc.relation.ispartof.spa.fl_str_mv |
Postgraduate Medicine, ISSN:325481, Vol.124, No.4 (2012); pp. 7-13 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871672045&doi=10.3810%2fpgm.2012.07.2560&partnerID=40&md5=21be1c7dca5cef8c3cdceae6cbfe21b5 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Medquest Communications LLC |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167570388877312 |